New test detects residual cancer DNA in the blood without relying on tumour data

Pinterest LinkedIn Tumblr +

After patients with cancer undergo surgery to remove a tumour and sometimes additional chemotherapy, tools are used to identify patients at the highest risk of recurrence.

Non-invasive tools to detect microscopic disease are of especially high value. In a new study published in Clinical Cancer Research, a team led by investigators at Massachusetts General Hospital (MGH) USA, has evaluated the first “tumour-uninformed” test that detects cancer DNA circulating in the blood of patients following treatment.

The test, called Guardant Reveal, developed by precision oncology company Guardant Health, is “tumour-uninformed” because, unlike previous tests for circulating tumour DNA (ctDNA) in the blood, this test does not require knowing the particular mutations that were present in the patient’s tumour.

“The use of ctDNA, which is a type of liquid biopsy, is a powerful prognostic tool to detect residual disease, and many prospective trials are underway in the United States, Europe, Asia and Australia to use ctDNA to guide treatment decision-making,” says lead author Aparna R. Parikh, MD, an investigator in the Division of Hematology and Oncology at MGH and an assistant professor of Medicine at Harvard Medical School.

“Most studies have used a tumour-informed ctDNA approach that requires testing of the tumour and knowledge of tumour-specific alterations, which can’t be used when a patient has insufficient tumour tissue for analysis.”

In this study, Parikh and her colleagues at MGH and Guardant Health evaluated the first tumour-uninformed ctDNA assay to detect residual cancer cells in patients who underwent surgery for colorectal cancer. Instead of relying on DNA sequencing of individual patient’s tumours, the approach looked for known cancer-specific alterations.

When the researchers analysed ctDNA results from 84 patients and examined how accurately the results correlated with cancer recurrence, they found that this “plasma only” approach was similar in sensitivity and specificity to tumour-informed approaches.

“This is one of the first studies to report on a plasma-only approach.

There are advantages and disadvantages to each of the approaches,” says Parikh.

She notes that ongoing prospective studies will provide additional information on the performance of this assay for detecting residual cancer cells and for guiding treatment decisions.

Source: Massachusetts General Hospital


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.